Related Experiment Video

Updated: May 10, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

[Clinical research of crizotinib in advanced non-small cell lung cancer]

Haibo Zhu1, Xiaoyu Xu, Ling Wang

  • 1Dalian Medical University, Dalian 116044, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|June 18, 2013
PubMed

Insights

Crizotinib is an effective targeted therapy for non-small cell lung cancer (NSCLC) with EML4-ALK or ROS1 rearrangements. Further research is needed to understand and overcome drug resistance mechanisms in advanced NSCLC treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Targeted therapy is crucial in non-small cell lung cancer (NSCLC) treatment.
  • Crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, is a significant molecular targeted therapy for NSCLC.
  • Crizotinib is effective against EML4-ALK fusion genes and ROS1 rearrangements in advanced NSCLC.

Purpose of the Study:

  • To review the mechanism of action and pharmacokinetics of crizotinib.
  • To discuss the clinical progress of crizotinib in treating advanced NSCLC.
  • To highlight the need for further research into crizotinib drug resistance.

Main Methods:

  • Literature review of clinical trials and studies on crizotinib.
  • Analysis of pharmacokinetics and drug resistance mechanisms.
  • Synthesis of current clinical data on crizotinib efficacy in NSCLC.

Main Results:

  • Crizotinib demonstrates significant antitumor activity in advanced NSCLC patients with EML4-ALK mutations and ROS1 rearrangements.
  • Clinical trials show crizotinib is well-tolerated with minimal side effects.
  • Drug resistance to crizotinib has been observed, necessitating further investigation.

Conclusions:

  • Crizotinib is a valuable targeted therapy for specific NSCLC patient populations.
  • Understanding and overcoming drug resistance are critical for improving long-term treatment outcomes.
  • Continued research into crizotinib's mechanisms and resistance is essential for advancing NSCLC therapy.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...